for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kangmei Pharmaceutical Co Ltd

600518.SS

Latest Trade

3.64CNY

Change

-0.19(-4.96%)

Volume

78,527,735

Today's Range

3.64

 - 

3.76

52 Week Range

2.31

 - 

4.82

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.83
Open
3.70
Volume
78,527,735
3M AVG Volume
558.16
Today's High
3.76
Today's Low
3.64
52 Week High
4.82
52 Week Low
2.31
Shares Out (MIL)
4,932.90
Market Cap (MIL)
20,044.66
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Kangmei Pharma Takes Actions To Solve Operation Issues, Share Trade To Resume

Kangmei Pharmaceutical Swings To Net Loss Of 1.4 Bln Yuan In H1

Kangmei Pharmaceutical's Trading In Shares To Suspend From July 23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kangmei Pharmaceutical Co Ltd

Kangmei Pharmaceutical Co., Ltd is a China-based company, principally engaged in the manufacture and sales of pharmaceutical products. The Company's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The Company is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. It also engages in the provision of real estate leasing and distribution services, among others. The Company mainly conducts its businesses within domestic markets.

Industry

Biotechnology & Drugs

Contact Info

Taike Road, Xiameilin, Futian District

SHENZHEN, GNG

518000

China

+86.755.33187777

http://www.kangmei.com.cn

Executive Leadership

Jincheng Wan

Chief Financial Officer, Acting Secretary of the Board

Xinggu Ma

General Manager

Hanyao Ma

Deputy General Manager, Director

Zhongwei Han

Deputy General Manager

Jianhua Li

Deputy General Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
3.44
Price To Book (MRQ)
1.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
172.15
LT Debt To Equity (MRQ)
114.95
Return on Investment (TTM)
-13.63
Return on Equity (TTM)
-9.15

Latest News

Latest News

BRIEF-Kangmei Pharmaceutical's Owner Under Forceful Measures By Police For Suspected Violation

* SAYS ITS OWNER MA XINGTIAN IS UNDER FORCEFUL MEASURES BY POLICE FOR SUSPECTED VIOLATION OF INFORMATION DISCLOSURE

BRIEF-Kangmei Pharmaceutical Elects Chairman

* SAYS BOARD ELECTS MA XINGGU AS CHAIRMAN Source text in Chinese: https://bit.ly/2YPrSez Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Kangmei Pharmaceutical Swings To Net Losses In 2019, Q1

* SAYS 2019 NET LOSS AT 4.7 BILLION YUAN ($663.43 million) VERSUS NET PROFIT OF 374.5 MILLION YUAN YEAR EARLIER

BRIEF-Kangmei Pharmaceutical Sees 2019 Net Loss At 4.6 Bln Yuan

* SAYS IT SEES 2019 NET LOSS AT 4.6 BILLION YUAN ($647.23 million) FROM PREVIOUS ESTIMATE OF 1.35-1.65 BILLION YUAN NET LOSS Source text in Chinese: https://bit.ly/2zOC273 Further company coverage: ($1 = 7.1072 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Kangmei Pharma Fined, Three Former Exectutives Barred From Re-Entering Securities Market For Life

* SAYS ITS FORMER CHAIRMAN, VICE CHAIRWOMAN AND BOARD DIRECTOR FINED AND BARRED BY SECURITIES REGULATOR FROM RE-ENTERING THE SECURITIES MARKET FOR LIFE DUE TO DOCTORING ITS FINANCIAL REPORTS Source text in Chinese: https://bit.ly/3bES28w Further company coverage: (Reporting...

BRIEF-Kangmei Pharma, Senior Executives Warned For Information Disclosure Violation

* SAYS IT, SENIOR EXECUTIVES WARNED BY SECURITIES REGULATOR FOR INFORMATION DISCLOSURE VIOLATION Source text in Chinese: https://bit.ly/3biE3oG Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Kangmei Pharmaceutical issues 2018 first tranche super short-term financing notes worth 1.5 bln yuan

* Says it issued 2018 first tranche super short-term financing notes worth 1.5 billion yuan, with a term of 270 days and coupon rate of 5.38 percent

BRIEF-Kangmei Pharma Signs Agreement To Set Up Hospital With Partners

* SAYS IT SIGNS AGREEMENT TO INVEST ABOUT 1.08 BILLION YUAN ($165.60 million) TO SET UP HOSPITAL WITH PARTNERS Source text in Chinese: http://bit.ly/2Fk62Wa Further company coverage: ($1 = 6.5216 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Kangmei Pharmaceutical to acquire 80 pct stake in Huizhou-based pharmaceutical firm for 20.8 mln yuan

* Says it plans to acquire 80 percent stake in Huizhou-based pharmaceutical firm for 20.8 million yuan

BRIEF-Kangmei Pharmaceutical to invest 50 mln yuan to set up wholly owned medical appliances firm

* Says its unit will invest 50 million yuan to set up a Beijing-based wholly owned medical appliances firm

BRIEF-Kangmei Pharmaceutical in deal to invest 5 bln yuan in Guizhou

* SAYS IT SIGNS STRATEGIC AGREEMENT TO INVEST 5.0 BILLION YUAN ($756.06 million) IN GUIZHOU ON AREAS INCLUDING CHINESE MEDICINE RESEARCH, HEALTH BIG DATA Source text in Chinese: http://bit.ly/2Avc4TM Further company coverage: ($1 = 6.6132 Chinese yuan renminbi) (Reporting...

BRIEF-Kangmei Pharmaceutical's controlling shareholder issues 2017 second tranche exchangeable bonds worth 3 bln yuan

* Says its controlling shareholder issues 2017 second tranche non-public exchangeable bonds worth 3 billion yuan, with a term of three years

BRIEF-Kangmei Pharmaceutical says controlling shareholder issues 2017 1st tranche non-public exchangeable bonds worth 2 bln yuan

* Says co's controlling shareholder, an industry investment firm, issued 2017 first tranche non-public exchangeable bonds worth 2 billion yuan, with term of 3 years

BRIEF-Kangmei Pharmaceutical , BGI Genomics in strategic agreement

Kangmei Pharmaceutical Co Ltd , BGI Genomics Co LTd

BRIEF-Kangmei Pharmaceutical issues 2017 third tranche mid-term bills worth 2 bln yuan

* Says it issued 2017 third tranche mid-term bills worth 2 billion yuan with a term of 5 years, and coupon rate of 5.47 percent

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up